Evidence map›Paper›PMID 42389293›Full record

ReviewRSC chemical biology2026

Mechanism-based inhibition of zinc-dependent histone deacetylases.

David W Christianson

Abstract readReview
In one paragraph

Review in RSC chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David W ChristiansonRoy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania Philadelphia Pennsylvania 19104-6323 USA chris@sas.upenn.edu (215) 898-5714.ORCID https://orcid.org/0000-0002-0194-5212

Funding

Structure and Function of MetalloenzymesR01GM049758 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI CHRISTIANSON, DAVID W · 1994 to 2025
$7.6M
NIGMS NIH HHS R01 GM049758
6 · The paper itself

Abstract

The hallmark of a mechanism-based inhibitor is a chemical transformation that occurs upon binding in an enzyme active site that typically yields a more potent inhibitory species. A mechanism-based enzyme inhibitor can be a closely-related analogue of the native substrate, or it can be strikingly different in its structure. Here, the discovery of mechanism-based inhibitors is briefly reviewed to establish a foundation for understanding the mechanism-based inhibition of zinc-dependent histone deacetylases (HDACs), enzymes that play critical roles in epigenetics and the regulation of myriad cellular processes. Notably, the discovery of mechanism-based HDAC inhibition was an unexpected surprise emanating from X-ray crystal structures of enzyme-inhibitor complexes. In each example discussed, the C[double bond, length as m-dash]O, C[double bond, length as m-dash]N, or C[triple bond, length as m-dash]N group of an inhibitor undergoes nucleophilic attack by zinc-bound water in the same manner as the C[double bond, length as m-dash]O group of the native HDAC substrate; however, nucleophilic attack at the bound inhibitor leads to the formation of a tightly-bound enzyme-inhibitor complex. The dual requirements of steric fit as well as fitness for chemical activation can be exploited in unique strategies to enhance inhibitory potency and selectivity.

Identifiers

PMID42389293
PMCPMC13322759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.